$1.78
Value $204M
ELDN and TMO stock compared: price, dividend, valuation and results, from SEC filings.
$1.78
Value $204M
$669.54
Value $249B
Eledon Pharmaceuticals (ELDN) has a market value of $204M and Thermo Fisher Scientific (TMO) $249B. Over the last year, with dividends, ELDN moved +14.8% and TMO +17.1%. Dividend yield: ELDN none, TMO 0.27%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ELDN$204M
TMO$249B
TMO is 1,218 times ELDN
Revenue, 12 months
ELDN–
TMO$47.4B
Net income, 12 months
ELDN-$85M
TMO$7.1B
Operating margin
ELDN–
TMO17.9%
ROIC
ELDN-44.4%
TMO8.2%
52.6 points apart
P/E
ELDN–
TMO35.2
Dividend yield
ELDN0.0%
TMO0.3%
0.3 points apart
5-year return
ELDN-66.5%
TMO+6.8%
73.3 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ELDN-66.3%
TMO+6.8%
| Period | ELDNWith dividends | TMOWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | +14.8%Price +14.8% | +17.1%Price +16.7% |
| 3 years since November 20, 2023 | +45.9%+13.4% a yearPrice +45.9% | +44.1%+13.0% a yearPrice +42.7% |
| 5 years since November 19, 2021 | -66.5%-19.6% a yearPrice -66.5% | +6.8%+1.3% a yearPrice +5.3% |
| 10 years since November 22, 2016 | -99.0%-36.6% a yearPrice -99.0% | +381.6%+17.0% a yearPrice +368.2% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ELDNEledon PharmaceuticalsTMOThermo Fisher Scientific
| Price | $1.78 | $669.54 |
|---|---|---|
| Market value | $204M | $249B |
| Enterprise value (EV) | $135M | $284B |
| P/E | – | 35.2 |
| P/E, 5-year median | – | 32.7 |
| P/B | 6.6 | 4.5 |
| EV/EBIT | – | 33.5 |
| Free cash flow yield | – | 3.1% |
| Revenue, 12 months | – | $47.4B |
|---|---|---|
| Net income, 12 months | -$85M | $7.1B |
| Free cash flow, 12 months | -$78M | $7.6B |
| Earnings per share, 12 months | -$0.73 | $18.96 |
| Revenue growth, year on year | – | 3.9% |
| Revenue growth a year, past | – | +6.7%over 5 years |
| EPS growth a year, past | – | +2.1%over 5 years |
| Gross margin | – | – |
|---|---|---|
| Operating margin | – | 17.9% |
| Net margin | – | 14.9% |
| ROIC | -44.4% | 8.2% |
| ROE | -189.0% | 13.4% |
| Cash | $70M | $6.1B |
|---|---|---|
| Total debt | $376.0K | $41.4B |
| Net debt / EBITDA | – | 3.7 |
| Interest cover | – | 5.5× |
| Dividend yield | – | 0.3% |
|---|---|---|
| Dividend per share, 12 months | – | $1.84 |
| Dividend growth a year, past | – | +14.3%over 5 years |
| Buyback yield | – | 1.2% |
| Shareholder yield | – | 1.5% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Thermo Fisher Scientific ($249B) is about 1,218.0 times Eledon Pharmaceuticals ($204M), at today's prices.
Since November 22, 2016, ELDN's price moved -99.0% and TMO's +368.2%. With dividends: ELDN -99.0% (-36.6% a year), TMO +381.6% (+17.0% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Eledon Pharmaceuticals and 0.27% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.